These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1177 related items for PubMed ID: 20194844

  • 21. The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche.
    Main C, Pitt M, Moxham T, Stein K.
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):27-32. PubMed ID: 21047488
    [Abstract] [Full Text] [Related]

  • 22. Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia.
    Giles FJ, Shi GG, Cortes JE, Thomas D, Keating AR, Kantarjian HM, Keating MJ, O'Brien SM.
    Cancer Chemother Pharmacol; 2003 Sep; 52(3):223-8. PubMed ID: 12783199
    [Abstract] [Full Text] [Related]

  • 23. Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma.
    Sacchi S, Pozzi S, Marcheselli R, Federico M, Tucci A, Merli F, Orsucci L, Liberati M, Vallisa D, Brugiatelli M, Italian Lymphoma Study Group.
    Cancer; 2007 Jul 01; 110(1):121-8. PubMed ID: 17503433
    [Abstract] [Full Text] [Related]

  • 24. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
    Byrd JC, Gribben JG, Peterson BL, Grever MR, Lozanski G, Lucas DM, Lampson B, Larson RA, Caligiuri MA, Heerema NA.
    J Clin Oncol; 2006 Jan 20; 24(3):437-43. PubMed ID: 16344317
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma.
    Roberts JD, Smith MR, Feldman EJ, Cragg L, Millenson MM, Roboz GJ, Honeycutt C, Thune R, Padavic-Shaller K, Carter WH, Ramakrishnan V, Murgo AJ, Grant S.
    Clin Cancer Res; 2006 Oct 01; 12(19):5809-16. PubMed ID: 17020988
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
    Bosch F, Ferrer A, Villamor N, González M, Briones J, González-Barca E, Abella E, Gardella S, Escoda L, Pérez-Ceballos E, Asensi A, Sayas MJ, Font L, Altés A, Muntañola A, Bertazzoni P, Rozman M, Aymerich M, Giné E, Montserrat E.
    Clin Cancer Res; 2008 Jan 01; 14(1):155-61. PubMed ID: 18172266
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma.
    Czuczman MS, Koryzna A, Mohr A, Stewart C, Donohue K, Blumenson L, Bernstein ZP, McCarthy P, Alam A, Hernandez-Ilizaliturri F, Skipper M, Brown K, Chanan-Khan A, Klippenstein D, Loud P, Rock MK, Benyunes M, Grillo-Lopez A, Bernstein SH.
    J Clin Oncol; 2005 Feb 01; 23(4):694-704. PubMed ID: 15681517
    [Abstract] [Full Text] [Related]

  • 32. Fludarabine combined with cyclophosphamid is highly effective in the treatment of chronic lymphocytic leukemia.
    Tóthová E, Kafková A, Fricová M, Guman T, Stecová N.
    Neoplasma; 2003 Feb 01; 50(6):433-7. PubMed ID: 14689065
    [Abstract] [Full Text] [Related]

  • 33. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
    Tsimberidou AM, Keating MJ, Giles FJ, Wierda WG, Ferrajoli A, Lerner S, Beran M, Andreeff M, Kantarjian HM, O'Brien S.
    Cancer; 2004 Jun 15; 100(12):2583-91. PubMed ID: 15197800
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial.
    Elter T, Gercheva-Kyuchukova L, Pylylpenko H, Robak T, Jaksic B, Rekhtman G, Kyrcz-Krzemień S, Vatutin M, Wu J, Sirard C, Hallek M, Engert A.
    Lancet Oncol; 2011 Dec 15; 12(13):1204-13. PubMed ID: 21992852
    [Abstract] [Full Text] [Related]

  • 37. Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience.
    Herishanu Y, Goldschmidt N, Bairey O, Ruchlemer R, Fineman R, Rahimi-Levene N, Shvidel L, Tadmor T, Ariel A, Braester A, Shapiro M, Joffe E, Polliack A, Israeli CLL Study Group.
    Haematologica; 2015 May 15; 100(5):662-9. PubMed ID: 25661442
    [Abstract] [Full Text] [Related]

  • 38. Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia.
    Chow KU, Kim SZ, von Neuhoff N, Schlegelberger B, Stilgenbauer S, Wunderle L, Cordes HJ, Bergmann L.
    Eur J Haematol; 2011 Nov 15; 87(5):426-33. PubMed ID: 21749447
    [Abstract] [Full Text] [Related]

  • 39. Fludarabine + prednisone +/- alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized study.
    Mauro FR, Zinzani P, Zaja F, Gentile M, Vegna ML, Stefoni V, Marin L, Fanin R, Baccarani M, Tura S, Mandelli F.
    Haematologica; 2003 Dec 15; 88(12):1348-57. PubMed ID: 14687987
    [Abstract] [Full Text] [Related]

  • 40. Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies.
    Tam C, Seymour JF, Brown M, Campbell P, Scarlett J, Underhill C, Ritchie D, Bond R, Grigg AP.
    Haematologica; 2005 May 15; 90(5):700-2. PubMed ID: 15921393
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 59.